Skip to Main Content

Paper Details

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
Neuro Oncol
15
2022
GBM, IDH, IDHmut, IDHwt, gene panel, glioblastoma, patients, targeted gene panels, tumor
Author NameAffiliation
Mehdi TouatSorbonne Universite, Inserm, CNRS, Institut du Cerveau et de la Moelle epiniere, Hopitaux Universitaires La Pitie Salpetriere - Charles Foix
Tracy T BatchelorCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Tracy T BatchelorCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Omar ArnaoutBrigham and Women's Hospital, Harvard Medical School
Sandro SantagataCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Sandro SantagataBrigham and Women's Hospital and Harvard Medical School
Rameen BeroukhimCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Wenya Linda BiBrigham and Women's Hospital, Harvard Medical School
Keith L LigonCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Keith L LigonBrigham and Women's Hospital and Harvard Medical School
Keith L LigonDana-Farber Cancer Institute
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
  • 1 - 12

Datasets